XBiotech Inc. financial data

Symbol
XBIT on Nasdaq
Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 13 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2835% % 145%
Debt-to-equity 4.2% % -54%
Return On Equity -28% % -41%
Return On Assets -27% % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30,487,731 shares 0%
Common Stock, Shares, Outstanding 30,487,731 shares 0%
Entity Public Float $77,050,226 USD -37%
Common Stock, Value, Issued $276,727,000 USD 1.3%
Weighted Average Number of Shares Outstanding, Basic 30,487,731 shares 0.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $47,390,000 USD 26%
General and Administrative Expense $8,295,000 USD 76%
Operating Income (Loss) $55,685,000 USD -31%
Nonoperating Income (Expense) $10,380,000 USD 166%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $45,305,000 USD -17%
Income Tax Expense (Benefit) $235,000 USD
Net Income (Loss) Attributable to Parent $45,540,000 USD -18%
Earnings Per Share, Basic -1.49 USD/shares -18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $125,551,000 USD -27%
Accounts Receivable, after Allowance for Credit Loss, Current $450,000 USD -38%
Assets, Current $126,953,000 USD -27%
Property, Plant and Equipment, Net $23,129,000 USD -5.7%
Assets $150,082,000 USD -25%
Accounts Payable, Current $1,535,000 USD -31%
Employee-related Liabilities, Current $5,181,000 USD 748%
Accrued Liabilities, Current $6,318,000 USD 140%
Liabilities, Current $7,929,000 USD -48%
Accrued Income Taxes, Noncurrent $1,798,000 USD 4.5%
Deferred Income Tax Liabilities, Net $5,000 USD
Liabilities $9,732,000 USD -42%
Retained Earnings (Accumulated Deficit) $136,377,000 USD -50%
Stockholders' Equity Attributable to Parent $140,350,000 USD -23%
Liabilities and Equity $150,082,000 USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,720,000 USD 6.7%
Net Cash Provided by (Used in) Financing Activities $10,250,000 USD -202%
Net Cash Provided by (Used in) Investing Activities $94,000 USD 63%
Common Stock, Shares, Issued 30,487,731 shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,780,000 USD -1752%
Interest Paid, Excluding Capitalized Interest, Operating Activities $486,000 USD 22%
Deferred Tax Assets, Valuation Allowance $33,891,000 USD 28%
Deferred Tax Assets, Gross $34,069,000 USD 27%
Depreciation $442,000 USD 2.3%
Payments to Acquire Property, Plant, and Equipment $94,000 USD -63%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $38,531,000 USD -52%
Deferred Tax Assets, Operating Loss Carryforwards $15,184,000 USD 442%
Unrecognized Tax Benefits $3,716,000 USD 8.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $178,000 USD -55%
Share-based Payment Arrangement, Expense $3,622,000 USD 107%